ReviewInternal and emergency medicine2026
Beyond biomarkers: designer natriuretic peptides and cGMP centered therapies for cardiorenal and cardiometabolic protection in chronic heart failure.
Review in Internal and emergency medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic heart failure (CHF) remains a leading cause of morbidity and mortality worldwide, despite the improvement in guideline-directed medical therapy (GDMT). Natriuretic peptides (NPs), originally identified as diagnostic and prognostic biomarkers of HF, are now recognized as important regulators of cardiovascular, renal and metabolic homeostasis. The NP system, including atrial (ANP), B-type (BNP), and C-type (CNP) NPs, exerts protective effects through activation of particulate guanylyl cyclase receptors and, downstream, cyclic guanosine monophosphate (cGMP) signalling, thereby promoting natriuresis, vasodilation, anti-fibrotic and anti-inflammatory actions. In CHF, however, the effectiveness of this endogenous system is reduced, due to impaired NP bioactivity together with counter-regulatory neurohormonal activation, a phenomenon commonly referred to as "natriuretic peptide resistance". Recent advances in peptide engineering have enabled the development of novel designer NPs, including Cenderitide, aimed at restoring and enhancing their signalling. As a dual GC-A/GC-B dual-receptor agonist, Cenderitide represents a prototype of this approach, integrating renal-enhancing and anti-fibrotic effects while minimizing systemic haemodynamic perturbations. Additional engineered peptides, including ANX042, MANP, and CRRL269, as well as complementary approaches targeting the cGMP pathway, such as soluble guanylate cyclase (sGC) stimulators, neprilysin inhibitors, and GC-A positive allosteric modulators, are further expanding the therapeutic potential of NP-centred therapies. Beyond cardiovascular effects, NPs also influence metabolic regulation and renal function, highlighting their relevance in cardiometabolic disease. Collectively, these developments support a shift from the use of NPs solely as biomarkers toward their emerging role as therapeutic targets and agents in the treatment of CHF.
Indexed as
Identifiers
42645729What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.